5Wekerle H.The thymus in myasthenia gravis.Ann N Y Acad Sci,1993,681:47-55.
6Palace J, Vincent A, Beeson D.Myasthenia gravis: diagnostic and management dilemmas. Curr Opin Neurol, 2001,14:583-589.
7Gautel M, Lakey A, Barlow DP, et al. Titin antibodies in myasthenia gravis:identification of a major immunogenic region of titin.Neurology ,1993,43:1581-1585.
8Mygland A, Aarli JA, Matre R, et al. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis.J Neurol Neurosurg Psychiatry, 1994,57:843-846.
9Tu LH, Cai GY, Zhu XM, et al .Using histochemical methods to study pathological features of hyperplastic thymus and thymoma in patients with myasthenia gravis. Ann N Y Acad Sci,1998,841:427-429.
10Müller-Hermelink HK, Marx A. Pathologic aspects of malignant and benign thymic disorders. Ann Med,1999,31 Suppl 2 :5-14.
3Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG):epidemiological data and prognostic factors[J]. Ann NY Acad Sci,2003,9(998) :413-423.
4AAEM Quality Assurance Committee. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenie syndrome[J ]. M uscle Nerve, 2001,24 (9) : 1239 -1247.
6Cornelio F, Peluchetti D, Mantegazza R, et al. The course of myasthenia gravis in patients treated with corticosteroids,azathioprine, and plasmapheresis[J]. Ann N Y Acad Sci, 1987, 505:517-525.
7Kanzaki M, Obara T, Sasano S, et al. Long-term clinical outcome after extended thymectomy combined postoperative high dose steroid therapy for juvenile myasthenia gravis[J]. Ann Thorac Cardiovasc Surg, 2008,14 ( 2 ) : 119-122.
